Analyst Maintains Buy Rating on Regeneron Pharmaceuticals
Analyst Tazeen Ahmad has maintained a 'Buy' rating and a $1,030 price target for Regeneron Pharmaceuticals, Inc.
Stocks · News reference
Alnylam And Regeneron Says Data Published In The The New England Journal Of Medicine, Reports Up To 80% Reduction In Liver Fat Sustained For 36 Weeks After Single CIDEBsiRNA Dose In MASLD Patients
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Regeneron Recognized in BioSpace 2027 Best Places to Work List
Regeneron was named among the top 20 large employers in the life sciences industry in BioSpace's 2027 Best Places to Work rankings.
Alnylam Collaborator Regeneron Reports Positive First-in-Human Results for CIDEBsiRNA
Alnylam Pharmaceuticals announced that its collaborator, Regeneron Pharmaceuticals, shared initial positive results from a first-in-human trial of CIDEBsiRNA in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD).
Type 2 Diabetes Clinical Trial and Competitive Landscape Analysis: 200+ Key Companies Shaping the Future of Type 2 Diabetes Therapeutics Space | DelveInsight
DelveInsight released a comprehensive report on the Type 2 Diabetes competitive landscape, analyzing 200+ pipeline drugs from 170+ active players. The report highlights recent approvals including Eli Lilly's FOUNDAYO (orforglipron) and Novo Nordisk's once-weekly insulin options, alongside promising pipeline therapies targeting various mechanisms of action. Key developments include positive Phase III results for CagriSema, elecoglipron, and other novel GLP-1 receptor agonists, with approximately 60+ drugs in late-stage development.
Soleo Health Named Specialty Pharmacy Partner for Regeneron's Pasatru™
Soleo Health has been selected as a specialty pharmacy partner to support the distribution and patient access for Regeneron's FDA-approved treatment, Pasatru™ (garetosmab-grts).
Citigroup Adjusts Alnylam Pharmaceuticals Price Target
Citigroup has revised its price target for Alnylam Pharmaceuticals, Inc., lowering it from $320 to $250.